Pulmonary embolism treatment approach

To go back to the wikidoc page on VTE, click click here

Resident Survival Guide

Editor(s)-In-Chief: C. Michael Gibson, M.S., M.D. [1], The APEX Trial Investigators; Associate Editor(s)-In-Chief: Joseph Nasr, M.D.[2]; Rim Halaby, M.D. [3]

This page provides algorithms about the treatment choices. For more details about the medical therapy, click here. For more details about embolectomy, click here.

Prompt recognition, diagnosis, and treatment of acute pulmonary embolism is critical. Management requires early risk stratification, timely anticoagulation unless absolutely contraindicated, and escalation to advanced therapy when there is cardiopulmonary compromise. The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN guideline introduced five Acute PE Clinical Categories (A to E) to better guide care setting and therapy selection.^[1][2] Direct oral anticoagulants are preferred oral agents for most eligible patients. Low molecular weight heparin is preferred over unfractionated heparin for most patients requiring initial parenteral anticoagulation, whereas unfractionated heparin is generally favored when rapid reversal may be needed or advanced therapy is anticipated.^[1]

Shown below is an algorithm depicting the updated initial diagnostic approach to acute pulmonary embolism.^[3][1]

Diagnostic notes:

• PERC rule: Apply only when clinical gestalt suggests very low pretest probability.
• Age-adjusted D-dimer: In patients age 50 years or older, threshold = age × 10 μg/L FEU.
• YEARS algorithm: May be used in appropriate patients to reduce unnecessary CTPA.
• Pregnancy: Pregnancy-adapted YEARS may be used in selected pregnant patients.
• CTPA: Preferred imaging modality for most patients when not contraindicated.
• V/Q scan: Alternative when CTPA is contraindicated or undesirable.^[1]

Risk stratification in acute pulmonary embolism guides level of monitoring, disposition, and consideration of advanced therapies. Contemporary management incorporates hemodynamic status, markers of right ventricular dysfunction, biomarkers, clinical severity scores, and evidence of end-organ hypoperfusion.^[1][3]

High-risk features include persistent hypotension, vasopressor requirement, or cardiac arrest.^[1]

Clinical severity tools that may support risk assessment include:

• PESI
• sPESI
• Hestia criteria
• Bova score

Markers of increased severity include:

• Right ventricular enlargement or dysfunction on echocardiography or CTPA
• Elevated troponin
• Elevated BNP or NT-proBNP
• Hypoxemia, tachypnea, or escalating oxygen requirement
• Lactate elevation or other evidence of end-organ hypoperfusion^[1]

Shown below is an algorithm depicting the initial management of acute pulmonary embolism using the 2026 acute PE clinical categories.^[1][4]

Definitions used for risk stratification and category assignment:

• Low clinical severity score: PESI ≤85 (Class I to II) OR sPESI = 0 OR Hestia = 0 OR Bova ≤4
• Elevated clinical severity score: PESI >85 OR sPESI ≥1 OR Hestia ≥1 OR Bova >4
• RV dysfunction: RV/LV ratio >1.0 on CTPA or echocardiography, or RV hypokinesis on echo
• Abnormal biomarkers: Troponin above institutional upper limit of normal, or BNP / NT-proBNP elevation
• Respiratory modifier: RR >30/min, OR SpO₂ <90% on room air, OR substantial supplemental oxygen requirement, OR need for non-invasive ventilation
• Transient hypotension: SBP <90 mmHg OR drop >40 mmHg lasting <15 min OR responding to IV fluids
• Normotensive shock: End-organ hypoperfusion without persistent hypotension, such as elevated lactate, acute kidney injury, low urine output, mental status change, low cardiac index, or low MAP.^[1]

The long term management of PE depends on recurrence risk, whether the event was associated with a major reversible risk factor, whether persistent risk factors are present, and the patient’s bleeding risk. For most non-cancer patients, a direct oral anticoagulant is preferred over vitamin K antagonist therapy when not contraindicated. In selected cancer patients, either a DOAC or low molecular weight heparin may be used, with LMWH favored when bleeding risk from certain GI or GU cancers or drug interactions is a concern. The risk versus benefit of extended anticoagulation therapy should be reassessed regularly, such as annually.^[1][3][5]

Structured follow up after acute pulmonary embolism is important to assess symptoms, anticoagulation adherence, bleeding risk, recovery of functional status, and possible chronic thromboembolic pulmonary disease. Patients with persistent dyspnea or exercise limitation after PE should undergo further evaluation, commonly beginning with a V/Q scan when CTEPD or CTEPH is suspected.^[1]

• Confirm access to anticoagulation and follow up plan before discharge.
• Reassess dyspnea, exercise limitation, and functional impairment at follow up visits.
• Evaluate persistent symptoms after approximately 3 months for post-PE syndrome or chronic thromboembolic disease.
• Reassess bleeding risk and the ongoing need for anticoagulation periodically.^[1]

PESI and sPESI may help identify patients at low risk for short term complications and may support outpatient treatment decisions when used together with clinical judgment and other discharge criteria.^[1][3]

• PESI
• sPESI

• Direct oral anticoagulants are preferred oral agents for most eligible patients with acute PE.^[1]
• Low molecular weight heparin is preferred over unfractionated heparin for most non-high-risk patients requiring initial parenteral treatment.^[1]
• IV unfractionated heparin is preferred when thrombolysis, embolectomy, or another rapid change in therapy may be needed.^[1]
• Do not use outpatient treatment casually. It is appropriate only for carefully selected low-risk patients with reliable follow-up and immediate access to anticoagulation.^[1]
• Do not treat all intermediate-risk PE the same way. Presence of RV dysfunction, biomarkers, oxygen requirement, and clinical deterioration changes management intensity.^[1]
• Systemic thrombolysis is not routine therapy for stable patients. It is mainly reserved for patients with hemodynamic collapse or selected patients with significant deterioration and acceptable bleeding risk.^[1]
• Do not overuse IVC filters. They are generally reserved for acute VTE with an absolute contraindication to anticoagulation or selected failure cases.
• Do not forget follow up. Persistent dyspnea or functional limitation after PE should prompt evaluation for post-PE syndrome or chronic thromboembolic disease.^[1]
• Reassess anticoagulation duration deliberately. Extended therapy depends on recurrence risk, bleeding risk, and whether the event was associated with a major reversible risk factor.^[1][3]

Template:WH Template:WS